APMD Apnimed, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1745648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.14x
Current ratio9.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $2.48M | $12.08M | — | $8.80M | $17.11M | — |
| R&D expense | $11.81M | $9.90M | — | $9.75M | $15.97M | — |
| SG&A expense | $22.63M | $12.67M | — | $6.04M | $5.35M | — |
| Operating income | -$32.20M | -$11.70M | — | -$8.98M | -$5.94M | — |
| Pretax income | -$29.52M | $40.73M | — | -$8.72M | -$5.63M | — |
| Income tax | — | $0 | — | — | $0 | — |
| Net income | -$29.52M | $125.94M | $67.72M | -$10.91M | -$69.47M | -$28.65M |
| EBITDA | -$32.20M | — | — | -$8.98M | — | — |
| EPS (basic) | -1.05 | — | — | -2.29 | — | — |
| EPS (diluted) | -1.05 | — | — | -2.29 | — | — |
| Weighted avg. shares (diluted) | 28.02M | 32.35M | — | 4.77M | 4.75M | — |
| Balance sheet | ||||||
| Cash & equivalents | $351.83M | $172.80M | — | $56.62M | — | — |
| Receivables | $588,000 | $690,000 | — | — | — | — |
| Current assets | $360.96M | $184.77M | — | — | — | — |
| PP&E, net | $46,000 | $53,000 | — | — | — | — |
| Total assets | $371.49M | $195.46M | — | — | — | — |
| Current liabilities | $36.96M | $35.58M | — | — | — | — |
| Long-term debt | $39.06M | $40.27M | — | — | — | — |
| Total debt | $39.06M | $40.27M | — | — | — | — |
| Total liabilities | $86.73M | $125.70M | — | — | — | — |
| Shareholders' equity | $284.76M | -$176.18M | -$304.12M | -$354.64M | -$345.03M | -$276.46M |
| Net debt | -$312.77M | -$132.54M | — | — | — | — |
| Shares outstanding | 41.63M | 4.80M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$21.18M | — | — | -$17.27M | — | — |
| Investing cash flow | $0 | — | — | $0 | — | — |
| Financing cash flow | $200.70M | — | — | $35.07M | — | — |
| Depreciation & amortization | $7,000 | — | — | $8,000 | — | — |
| Stock-based compensation | $6.27M | — | — | $1.23M | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.